These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Multidrug maestro: 20 years on the trail of HIV. An interview with Martin S. Hirsch. Interview by Mark Mascolini. Hirsch MS IAPAC Mon; 2001 Apr; 7(4):104-9, 113. PubMed ID: 11700604 [No Abstract] [Full Text] [Related]
44. Integration of salvage research into existing networks and structures. Evans D Res Initiat Treat Action; 2004; 10(1):22-3. PubMed ID: 15595168 [No Abstract] [Full Text] [Related]
45. Intent-to-treat analysis. Kravcik S HIV Clin Trials; 2003; 4(6):425. PubMed ID: 14677539 [No Abstract] [Full Text] [Related]
48. The mixed message. Jones M Nurs Times; 1997 Aug 27-Sep 2; 93(35):22-4. PubMed ID: 9380549 [No Abstract] [Full Text] [Related]
49. Behind the frontline. A doctor looks at combos & side effects. Vázquez E Posit Aware; 2003; 14(1):63-4. PubMed ID: 12630377 [No Abstract] [Full Text] [Related]
51. Mix and match. With as many as six drug categories, more than ever, how to treat HIV can become a matter of strategy. Gallant J Posit Aware; 2010; 21(2):18-9. PubMed ID: 20524347 [No Abstract] [Full Text] [Related]
52. HIV therapy after treatment interruption in patients with multiple failure and more than 200 CD4+ T lymphocyte count. Jaafar A; Massip P; Sandres-Sauné K; Souyris C; Pasquier C; Aquilina C; Izopet J J Med Virol; 2004 Sep; 74(1):8-15. PubMed ID: 15258962 [TBL] [Abstract][Full Text] [Related]
53. Antiretroviral therapy roundup from CROI. Report on newer drugs in development and some already approved drugs. Berry J Posit Aware; 2008; 19(3):20-3. PubMed ID: 18724440 [No Abstract] [Full Text] [Related]
54. Creating a friendly environment for your HIV medications. The effect of interactions. Zive JL; Learned J Posit Aware; 2005; Spec No():16-21. PubMed ID: 16335474 [No Abstract] [Full Text] [Related]
55. Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype. Izopet J; Souyris C; Sandres-Sauné K; Puissant B; Obadia M; Pasquier C; Puel J; Blancher A; Massip P J Med Virol; 2002 Nov; 68(3):305-10. PubMed ID: 12226815 [TBL] [Abstract][Full Text] [Related]
56. When to start, when to STI (or, groping for the golden moment). Mascolini M IAPAC Mon; 2001 Apr; 7(4):114-7, 120-31. PubMed ID: 11700605 [No Abstract] [Full Text] [Related]
57. Treatment interruption; advanced HIV; new ideas: Dr. Cal Cohen interview on retrovirus conference (part 2 or 2). Interview by John S. James. Cohen C AIDS Treat News; 2003 Apr; (390):2-5. PubMed ID: 12739473 [TBL] [Abstract][Full Text] [Related]
58. New targets, new drugs, failed trials and the need for more information. Becker SL Posit Aware; 2004; 15(1):12-3. PubMed ID: 14989194 [No Abstract] [Full Text] [Related]
59. The Salvage Therapy II Think Tank. Newcomb-Fernandez J Res Initiat Treat Action; 2004; 10(1):8-21. PubMed ID: 15595167 [No Abstract] [Full Text] [Related]